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Abstract: Pancreatic cancer (PC) is characterized by metabolic deregulations that often manifest as
deviations in metabolite levels and aberrations in their corresponding metabolic genes across the
clinical specimens and preclinical PC models. Cholesterol is one of the critical metabolites supporting
PC, synthesized or acquired by PC cells. Nevertheless, the significance of the de novo cholesterol
synthesis pathway has been controversial in PC, indicating the need to reassess this pathway in PC.
We utilized preclinical models and clinical specimens of PC patients and cell lines and utilized mass
spectrometry-based sterol analysis. Further, we also performed in silico analysis to corroborate the
significance of de novo cholesterol synthesis pathway in PC. Our results demonstrated alteration
in free sterol levels, including free cholesterol, across in vitro, in vivo, and clinical specimens of
PC. Especially, our sterol analyses established consistent alterations in free cholesterol across the
different PC models. Overall, this study demonstrates the significance and consistency in deviation of
cholesterol synthesis pathway in PC while showing the aberrations in sterol metabolite intermediates
and the related genes using preclinical models, in silico platforms, and the clinical specimens.
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1. Introduction

published maps and institutional affil-

Cholesterol is a vital structural component of cellular membranes and plays a key role
in various biological processes involving physiology and disease progression, including
cancer [1,2]. Due to the cellular utilization of free cholesterol as a membrane constituent
and an intermediate in sterol metabolism, free cholesterol pools become significantly
decreased in cells, thus leading to cellular dependence on cholesterol replenishment for vital
processes [3]. Such striking reliance on cholesterol replenishment, including the de novo
biosynthesis of cholesterol, is noticed in malignancies, wherein cancer cells exhibit prolific
division and migration potential, and abnormally rely on cholesterol to maintain their
proliferative and migratory competence [2,4–6]. Such aberrant cholesterol dependence often
manifests as deviations in abundance of cholesterol and the intermediates of the cholesterol
synthesis pathway in cancer tissues [3,7].
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Pancreatic cancer (PC) is characterized by rapid growth evident at dismal stages of the
disease, and pancreatic tumor cells exhibit consistent proliferative and migration potential
at early as well as at dismal stages of cancer [8,9]. Oncogenic mutations, including the most
frequent KRASG12D mutation, promote the proliferative and migratory capacity in PC
cells [10]. In addition to the stimulus provided by the oncogenes, PC cells also require
oncogene-driven metabolism, of which cholesterol metabolism plays a crucial role in the
pathological phenotype of PC [11,12]. Cholesterol metabolism impacts survival in both
the clinical and preclinical contexts of PC [12]. Independent studies supported the notion
of PC’s dependence on cholesterol through in vitro, in vivo, and in silico analyses [11,12].
While uptake of cholesterol for in vitro growth by PC cells was established [13]; deletion of
cholesterol metabolic genes also showed cytostatic effects on Kras-driven tumor growth,
in vivo in mouse PC models [12]. Furthermore, retrospective studies revealed poor survival
outcomes in PC patients associated with sterol metabolic genes [12,14]. Thus, in vitro and
in vivo models of PC reveal an inevitable association between cholesterol synthesis and
growth, survival, as well as therapy response of PC, which is strongly supported by
retrospective survival analyses [12].
We have previously shown that cholesterol metabolism plays a vital role in the radiation resistance of PC, and blockage of cholesterol synthesis sensitizes PC to radiation [15].
Based on the previous observations indicating dependence of PC on cholesterol synthesis
pathway, we hypothesized that free cholesterol and cholesterol synthesis intermediates alter
across different models of PC. Quantification of free cholesterol and sterol intermediates
in cholesterol biosynthesis become critical to unveil the pathological role of cholesterol
metabolism in disease [16,17], which is pertinent to our hypothesis. Such quantitation of
cholesterol and its upstream metabolites preferably enumerates the fluctuations in cholesterol synthesis associated with disease, including cancers [16,18]. However, discrepancies
in sterol content across biological models [19] and the lack of comparative analyses of
cholesterol metabolites from a range of malignant specimens, including the in vitro, in vivo,
and clinical specimens [20] of a single cancer model, impede the possibility of correlating
the metabolite readouts across multiple specimen platforms within cancer.
In the current study, we have utilized the in silico analysis, clinical specimens, and
in vitro and in vivo models of pancreatic ductal adenocarcinoma for enumerating the
aberrant cholesterol synthesis pathway in PC. Our study sheds light on the consistency in
the deviation of cholesterol abundance and its synthesis across the biological specimens
of PC. We focused on the alterations in gene expression patterns involved in cholesterol
synthesis pathway, quantification of free sterols comprising cholesterol synthesis pathway,
and the prognostic outcomes of the genes involved in cholesterol synthesis pathway in PC.
2. Results
2.1. Higher Expression of Cholesterol Synthesis Genes in Human Pancreatic Ductal Adenocarcinoma
Pancreatic malignancies are histologically well-characterized exocrine lesions that can
progress from three precursor lesions, namely, intraductal papillary mucinous-neoplasms
(IPMNs), intraductal papillary-mucinous adenomas (IPMAs), and pancreatic intraepithelial
neoplasms (PanINs), to pancreatic ductal adenocarcinoma (PDAC) through oncogenic transformation and mutations in tumor suppressor genes (Figure 1A). Along with histological
abnormalities, malignant transformation also drives metabolic deviations in PC, as evident
in the mouse models of PC [21,22]. Anabolism of cholesterol constitutes a series of regulated biosynthesis steps, which have been least studied in the progression of PC. Cholesterol
biosynthesis initiates with Acetyl-CoA followed by sequential intermediates comprising
hydroxymethylglutaryl-CoA (HMG-CoA), mevalonate, farnesylpyrophosphate, lanosterol,
desmosterol, and 7-dehydrocholesterol (7-DHC), to name a few intermediates (Figure 1B).
In our analysis, human pancreatic tumors and premalignant lesions exhibited alterations
in gene expression patterns related to the enzymes involved in the cholesterol synthesis
pathway as shown in Figure 1C,D. As presented in heatmaps, the expression patterns of
sterol synthesis enzymes such as hydroxymethylglutaryl-CoA syntahse-1 (HMGCS1), 3-
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hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), squalene epoxidase (SQLE),
NAD(P)-dependent steroid dehydrogenase-like (NSDHL) protein, β-hydroxysteroid-d(8),d(7)isomerase (EBP), and 24-dehydrocholesterol reductase (DHCR24) were significantly upregulated in the human pancreatic tissues of malignant cohorts compared to normal pancreas
(Figure 1C,D). Relative expression patterns obtained from the dataset GSE19650 revealed
differences in expression of cholesterol synthesis genes among the normal, premalignant (IPMNs and IPMAs), and PDAC categories (Figure 1C). Furthermore, evaluating
the difference between normal and malignant pancreatic tissues with higher tumor cellularity revealed consistent upregulation of genes involved in cholesterol synthesis in
PC (Figure 1D). Nevertheless, there is significant upregulation of 13 cholesterol biosynthetic pathway genes in the pancreatic cancer compared to cancer-adjacent normal tissues
(Figure 1C) in the GSE19650 dataset. When we compared pancreatic cancer tissue with
high cellularity, we observed only three genes were significantly overexpressed in a PC
patient’s tissues compared to cancer-adjacent normal tissues (GSE32676) (Figure 1D).

Figure 1. Changes in cholesterol synthesis pathways in pancreatic cancer. (A) A schematic of
pancreatic cancer progression. (B) List of some of the enzymes and metabolic intermediates involved
in the cholesterol biosynthesis pathway. (C,D) Heatmaps of alterations in cholesterol synthesis
enzymes in pancreatic cancer. Color gradient: red, black, to green in each row of the heatmaps
indicates relative differences in the gene expression patterns as indicated by the scale provided below
the heatmap. The significant changes are marked with * <0.05; ** <0.01; *** <0.001.
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2.2. Sterol Alterations in Human Pancreatic Tumors
To determine if the changes in the gene expression (Figure 1C,D) translate into
changes in sterols, we measured the levels of sterols in human pancreatic tissues using LC–MS/MS method. Our method included the comparative analysis of unesterified
free sterols from the patient tumors as well as from the cancer-adjacent normal pancreas.
We found a lack of significant alteration in levels of cholesterol intermediates lanosterol,
desmosterol, and dehydrocholesterol between the normal and tumor specimens. However, free cholesterol content was significantly elevated in pancreatic tumors compared
to the cancer-adjacent normal pancreas (Figure 2A). Pancreatic cancer patient specimens
often contain premalignant zones reflecting distinct stages of tumor development, primary
tumors, and the metastatic tissues from distant organs [8]. Therefore, we compared the
levels of free sterols among the patient specimens comprising the primary and metastatic
sites of collection. Apart from the cholesterol, which was higher in pancreatic tumors compared with normal tissues, other sterols analyzed in this pathway did not exhibit significant
differences among the normal, primary malignant pancreatic tissues, and metastatic tissues
(Figure 2A,B), this may be due to small sample size used in the current study.

Figure 2. Sterol changes in human pancreatic tissues. (A) Mean and standard error plots showing
sterol levels in normal human pancreatic tissues and pancreatic cancer tumors (PC) normalized with
the protein content of respective tissue specimen. (B) Mean and standard error plots showing sterol
levels in normal human pancreatic tissues, pancreatic tumors (PC), and metastatic pancreatic cancer
(Met PC) tissues normalized to protein content of the respective tissue specimen. * = 0.0622, indicates
significant difference in cholesterol comparing normal vs. PC obtained through Welch’s t-test.
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2.3. An Elevated Level of Serum Cholesterol in Human Pancreatic Cancer
Serum constitutes the source and sink for multiple metabolites, including cholesterol,
enabling noninvasive analysis of cholesterol in pathological scenarios, including cancer [23].
We performed sterol analysis using sera to verify if high free cholesterol levels in human
PC tumors are reflected in sera of the PC patients. Indeed, our analyses using sera from
PC patients showed significantly higher un-esterified cholesterol levels compared with
normal samples (Figure 3A). However, lanosterol, desmosterol, and dehydrocholesterol
did not differ significantly among these groups, this may be due to small sample size.
We further categorized the serum samples from PC patients into subtypes based on the
stage of patients during diagnosis. Our analyses revealed a significant increase in the
level of cholesterol in the PC stage 2B patient samples compared to the sera from healthy
individuals. Such a significant difference was not noticed in serum cholesterol content from
other stages of PC (2a, 3, and 4, respectively) in comparison to the normal serum samples
(Figure 3B). This result may be due to the very small cohort used in this study, and precise
interpretation of current outcomes in future studies is required to validate these findings.

Figure 3. Serum cholesterol levels are high in human pancreatic cancer. (A) Mean and standard deviation plots showing sterol levels in human sera collected from healthy (normal) and patients with pancreatic ductal adenocarcinoma (PDAC) normalized with the volume of the specimen. (B) Mean and SE
plots showing sterol levels in human normalized to serum volume and classified based on healthy
(normal) and stagewise progression of pancreatic cancer, including stages 2a, 2b, 3, and 4, respectively.
* indicates p < 0.05 obtained through unpaired t-test.
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2.4. Sterol Upregulation in Different Mouse Models of PDAC
Genetically engineered mouse models (GEMMs) were developed with either the
pancreas-specific expression of oncogenic KrasG12D through PdxCre (KC), or activation of
KrasG12D in combination with Trp53R172H through PdxCre (KPC). We observed the development of PanIN lesions at 5 and 10 weeks of age and subsequently cancer with metastases at
25 and 50 weeks of age in KC and KPC models, respectively. These mice models for PC recapitulate the human PC in the defined genetic and histopathological manner [24]. We utilized
the pancreas from normal, KrasG12D ;PdxCre (KC) and KrasG12D ;Trp53R172H ;PdxCre (KPC) mice
models and analyzed levels of free cholesterol and other sterols. We observed significantly
high cholesterol and desmosterol in mouse pancreatic tumor tissues collected from KPC
mice models compared to normal as well as KC mice (Figure 4).

Figure 4. Sterol levels increase in GEMM models of pancreatic cancer: Mean and standard deviation
plots showing sterol levels in normal, KrasG12D ;PdxCre (KC) and KrasG12D ;Trp53R172H ;PdxCre (KPC)
pancreatic tissues. *, ** and *** indicate p < 0.05, 0.01 and 0.001 respectively, obtained through
unpaired t-test.

2.5. Sterol Levels from In Vitro Models of PC
Human pancreatic cancer cell lines reveal dependence of pancreatic cancer on cholesterol metabolism in a therapeutic context [15]. However, sterol content could be altered
through either uptake or intracellular synthesis [25]. Therefore, we evaluated the sterol
content in PC cell lines.
As presented in Figure 5, the cellular content of sterol was significantly altered in PC
cell lines compared to the HPNE cells, with differences observed in cell lines and media
composition. The PC cell line, T3M4, cultured in either delipidated media or N2 media,
contained significantly higher cholesterol, desmosterol, and lanosterol than that of the
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HPNE cells. Though CFPAC1 and SW1990 cells had high desmosterol content when
cultured in either media, the cholesterol levels were only elevated in these cells compared
to HPNE in N2 media. Another PC cell line, COLO357, utilized in our study showed
significantly low sterol contents compared to the HPNE cells. Finally, dehydrocholesterol,
which is the precursor metabolite of either cholesterol or desmosterol, was significantly
low in all PC cell lines compared to the HPNE cells, indicating the conversion of 7-DHC to
cholesterol in PC cells compared to normal HPNE cells.

Figure 5. Sterol levels in pancreatic cancer cell lines alter with lipid deprivation. Mean and standard
deviation bar plots depicting sterol quantification from immortalized pancreatic epithelial cell line
(HPNE) and pancreatic ductal carcinoma cell lines (CFAPC1, SW1990, T3M4, and COLO357) grown
in a delipidated medium are shown in panel (A), and N2-supplemented medium is shown in panel
(B). *, **, and *** indicate p < 0.01, <0.05, and <0.001, respectively, which were obtained through
one-way ANOVA analysis.

2.6. Patient Survival Is Dependent on Cholesterol Metabolism-Associated Genes in PC
To evaluate the overall impact of altered cholesterol synthesis on the survival of PC
patients, we compared the patient survival relative to the gene expression levels of sterol
biosynthesis enzymes. We found that the survival of PC patients declined with an elevated
expression of the following cholesterol synthesis pathway genes: FDFT1, SQLE, DHCR7,
DHCR24, and EBP (Figure 6).
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Figure 6. Genes involved in cholesterol synthesis affect patient survival in PDAC. Kaplan–Meier
survival curves reflecting the impact of cholesterol metabolic genes expression on patient survival
in PDAC.

3. Discussion
Pancreatic ductal adenocarcinoma possesses hyperplastic and neoplastic tumor lesions
(Figure 1A) originating spontaneously from the exocrine pancreas [26,27]. Neoplastic, transformed PC relies on a metabolic upsurge, including high cholesterol, to maintain survival
and proliferation, which could be compensated through de novo cholesterol synthesis [28].
The dependence of malignant cells on de novo cholesterol biosynthesis is so prominent that
the Kandutsch–Russell branch (Figure 1B) of the cholesterol synthesis pathway was first
described in cancer cells [29]; thus, metabolically demarcating malignancies from normal
tissues. Such demarcation can be revealed through alteration in expression of metabolic
genes, as evident from the upregulation of genes involved in cholesterol biosynthesis in PC
patient cohorts in our study (Figure 1C,D). Similar comparisons of cholesterol synthesis
gene expression patterns between normal and malignant cohorts have been utilized to
reveal and target cholesterol synthesis pathway in cancer [30,31]. Our study indicates upregulation of multiple genes that are particularly enzymes involved in cholesterol biosynthesis,
i.e., GGPS1, SQLE, FDPS, HMGCS1, and HMGCR, which were also reported in distinct
cancer models [30–38]. Such comparisons led to enumeration of the role of individual genes
involved in cholesterol synthesis pathway in different cancer models including PC [30,35].
Sterol analysis provides direct evidence of abnormal cholesterol metabolism and often corroborates with sterol gene expression patterns in cancer [39]. In our study, high
free cholesterol levels in PC tumors compared to the normal pancreatic tissues reflect
two possibilities: accumulation of free cholesterol in tumors through uptake of cholesterol and its precursors from extra tumoral sources, as shown previously [11], or elevated
cholesterol biosynthesis within tumors [14]. Based on higher free cholesterol in pancreatic
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tumors (as shown in Figure 2A), along with the upregulation of cholesterol biosynthesis
genes in pancreatic cancer patients, we conclude that the cholesterol biosynthesis pathway (Figure 1C,D) is undoubtedly upregulated in pancreatic cancer patients and in PC
tumors when combined with metastatic sites, which could be supported by the notion that
cholesterol maintains growth and metastasis in PC [12,13]. However, the lack of significant
differences in sterol levels other than free cholesterol in our analysis leaves scope for future
studies involving a greater number of samples to address the role of cholesterol metabolic
pathway intermediates in PC pathogenesis.
Tumor metabolism is often reflected by abnormal metabolic profiles in nontumoral
tissues like plasma [40]. We demonstrate high free cholesterol levels from serum samples
in PC (Figure 3A), which could serve as an indication of upregulated cholesterol synthesis
in pancreatic tumors. Furthermore, high free cholesterol levels in sera from stage 2b patient
samples of pancreatic cancer (Figure 3B) indicate that serum cholesterol levels alter with
the progression of pancreatic cancer. Previous studies reported controversial correlations
between high serum cholesterol and pancreatic cancer incidence [41,42]. Moreover, recent
findings indicate that the impact of cholesterol metabolism on PC would be affected by
genomic perturbations prevalent in this cancer [28]. Despite the ambiguity of metabolic perturbations from clinical specimens of PC, murine models have been ideal in recapitulating
metabolic deviation in PC. Our sterol analysis from murine PC models also substantiates
that sterol metabolites, especially cholesterol and DHC, are high in the pancreas of KPC
mice harboring activated KrasG12D and Trp53R172H compared to the normal pancreas and
KC mice (Figure 4), which indicates recapitulation of human pancreatic tumor sterol levels
in mice models of PC. Though human pancreatic cancer-derived cell lines recapitulate most
tumor cell metabolism in in vitro conditions [43], our analysis using pancreatic tumor cell
line models revealed heterogeneity in sterol content of PC cells in comparison to HPNE
cells. However, our study revealed higher cholesterol and its precursor levels in most of
the PC cell lines in lipid-deprived media, which substantiates high de novo cholesterol
synthesis in PC cells.
4. Materials and Methods
4.1. Chemicals
Unless otherwise noted, all chemicals were purchased from Sigma-Aldrich Co. (St. Louis,
MO, USA). HPLC-grade solvents were purchased from Thermo Fisher Scientific Inc.
(Waltham, MA, USA). All sterol standards, natural and isotopically labeled, used in this
study are available from Kerafast, Inc. (Boston, MA, USA).
4.2. Mice and Ethics Statement
We generated and characterized KrasG12D ;PdxCre (KC), and KrasG12D ;Trp53R172H ;PdxCre
(KPC) mouse models. The mice positive for Kras, Trp53, and PdxCre (Floxed KrasG12D and
Trp53R172H (KPC), 20–25 weeks old), as well as mice positive for Kras and PdxCre (Floxed
KrasG12D (KC), 40–50 weeks old), and their contemporary littermates (Unfloxed KrasG12D
(LSLKrasG12D ) of both sexes were utilized for this study [44]. The pancreas of each mouse
was resected and flash-frozen in liquid nitrogen. Throughout the study, the animals were
humanely treated and subjected to a 12 h of dark/light cycle with food and water ad libitum.
Animal studies were performed in accordance with the United States Public Health Service
“Guidelines for the Care and Use of Laboratory Animals” under an approved protocol by the University of Nebraska Medical Center’s Institutional Animal Care and Use
Committee (IACUC). Pancreatic tissue samples were frozen and kept at −80 ◦ C until
sterol extraction. Frozen pancreatic tissue samples were sonicated in ice-cold PBS containing butylated hydroxytoluene (BHT) and triphenylphosphine (PPh3). The aliquots of
homogenized tissue were used for sterol and oxysterol extractions and protein measurements. The protein was measured using a BCA assay (Pierce). Sterols were extracted
with Folch solution. The organic phase was dried in a speed vacuum, and samples were
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derivatized with Phenyltriazoledione (PTAD) as described in Section 4.6. Sterol levels were
normalized to protein measurements and expressed as nmol/mg protein.
4.3. Plasma and Pancreatic Tissue Preparation
Archived and deidentified serum samples were obtained for sterol analysis from the
Nebraska Biobank, UNMC, and stored at −80 ◦ C pending analysis. These samples included
serum processed from normal (healthy) and pancreatic cancer patient blood samples
available through Nebraska Biobank. Serum samples were thawed on ice during the
extraction, and 10 mL aliquots were taken for the sterol measurements. Sterols from 10 mL
aliquots were extracted without hydrolysis, derivatized with PTAD, and analyzed using
LC–MS/MS methods described previously [45]. Frozen pancreatic tumor tissues obtained
from PC patients and their adjacent normal pancreatic tissues were procured through Rapid
Autopsy Program, UNMC, and processed according to the method described in Section 2.2
for sterol analyses.
4.4. Cell Culture and Preparation
Human pancreatic cancer cell lines (CFPAC1, SW1990) and normal pancreatic cell
line HPNE were obtained from American Type Culture Collection, whereas T3M4 and
COLO357 were obtained from our collaborator. All the cell lines were validated by short
tandem repeat profiling (STR) DNA profiling at University of Nebraska Center (UNMC),
and before performing experiments, cell lines were tested for mycoplasma contamination.
Human pancreatic cancer cell line CFPAC1 was maintained in IMDM, while others, SW1990,
T3M4, and COLO357, were maintained in DMEM. In addition, basal medium with low
serum and epidermal growth factor was used to maintain the HPNE cell line. All media
were supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/mL penicillin
and 0.1 mg/mL streptomycin) at 37 ◦ C with 5% CO2 in a humidified atmosphere.
4.5. Metabolite Extraction from Cell Lines
Cells were seeded with an approximate density of 10,000 cells/well into 96-well plates
in their regular growth media. After several hours of cellular attachment, the medium was
replaced with defined media, which was either delipidated, serum-containing DMEM or N2
supplement medium, and cells were incubated for 48 h. At the end of incubation, Hoechst
dye was added, and the plate was imaged on ImageXpress Pico to count the total number
of cells per well. After that, the medium was removed, cells were rinsed twice with 1X PBS,
10 mL of antioxidant (butylated hydroxytoluene/sodium tripolyphosphate, BHT/TPP)
was added to each well, and the plate was frozen at −80 ◦ C until sterol extraction. For
sterol extraction, we added 200 mL of methanol per well and followed the analysis method
as described in our previous methodology [46].
4.6. LC–MS/MS (SRM) Analyses
Sterols were extracted and derivatized with PTAD as described previously [47] and
placed in an Acquity UPLC system equipped with an ANSI-compliant well plate holder
coupled to a Thermo Scientific TSQ Quantis mass spectrometer equipped with an APCI
source. Then, 5 µL of sample was injected onto the column (Phenomenex Luna Omega
C18, 1.6 µm, 100 Å, 2.1 mm × 50 mm) with 100% methanol (0.1% v/v acetic acid) mobile phase for 1.0 min runtime at a flow rate of 500 µL/min. Natural sterols were analyzed by selective reaction monitoring (SRM) using the following transitions: Chol 369 →
369, 7-DHC 560 → 365, 8-DHC 558 → 363, desmosterol 592 → 560, lanosterol 634 → 602,
with retention times of 0.7, 0.4, 0.4, 0.3, and 0.3 min, respectively. SRMs for the internal
standards were set to d7 -Chol 376 → 376, d7 -7-DHC 567 → 372, d7 -8-DHC 565 → 370,
13 C -desmosterol 595 → 563, 13 C -lanosterol 637 → 605. Final sterol numbers are reported
3
3
as nmol/mg of protein, and 7-DHC and 8-DHC are reported combined as dehydrocholesterol.
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4.7. Gene Expression and Survival Analyses
The publicly available, normalized datasets and their corresponding metadata (GSE19650
and GSE32676) were retrieved from Gene Expression Omnibus (GEO) repository [48]. Reactome cholesterol biosynthesis geneset from mSig database was used for the metabolic
gene expression profiling across the groups [49,50]. Kaplan–Meier survival analyses corresponding to effects of cholesterol synthesis pathway genes on PDAC patient survival were
retrieved using OncoLnc tool (http://www.oncolnc.org, accessed on 19 April 2021).
4.8. Statistics
Statistical analyses were performed using GraphPad Prism 9 for Windows and Microsoft Excel. An unpaired, two-tailed t-test was performed for individual comparisons
between two groups. Welch’s correction was employed when the variances between the two
groups were significantly different. Ordinary one-way ANOVA and multiple comparisons
with Tukey corrections were performed for comparisons between three or more groups.
The p-values for statistically significant differences are highlighted in the figure legends.
5. Conclusions
The cholesterol biosynthesis pathway plays a significant role in cellular metabolism
as it provides cholesterol and other sterol intermediates required for multiple metabolic
pathways associated with sterols [41,51]. Our in silico and metabolite analysis revealed the
upregulation of cholesterol biosynthesis in PC, which could explain the high cholesterol
levels in the plasma of PC patients, which has been of keen interest in cancer as a potential
target [52]. For instance, the upregulation of the rate-limiting enzyme HMGCR inevitably
enhances cholesterol synthesis in different malignancies, making it a predictable survival
marker and target in malignancies [37]. However, targeting HMGCR alone for curtailing
the cholesterol synthesis pathway using statins revealed controversial outcomes across
malignancies [53]. Thus, identification of cancer type-specific deviations in the cholesterol
biosynthesis would be more beneficial, and our study reveals that cholesterol synthesis is a
critical target in PC. However, enumeration of ideal targets, models, and their metabolic outcomes is warranted before optimal preclinical and clinical targeting of cholesterol synthesis
pathway could be achieved in PC. In the current study, we applied multiple modalities
to identify the upregulation of the cholesterol synthesis pathway in PC and confirmed
that clinical, in vivo, and in vitro models of PC could serve as complementary models to
decipher the exact functional involvement of cholesterol biosynthesis in PC. Furthermore,
our study also demonstrates the poor prognosis associated with the cholesterol metabolic
genes in PC. However, future studies using large patient cohort samples are warranted to
discriminate the prospective role of individual cholesterol biosynthesis steps in PC. Overall,
our study reflects the potential for individual PC models and applicability of in silico
and sterol analysis in identifying potential targets in the cholesterol synthesis pathway
in PDAC.
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